Milnacipran Hydrochloride

盐酸米那普仑

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameMilnacipran Hydrochloride
Drug Alias NameMidalcipran米那普仑盐酸盐Milnacipran Pierre Fabre Medicament盐酸米拉普仑milnacipran +[15] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin transporter inhibitorsNorepinephrine transporter inhibitors
TargetsNorepinephrine transporterSerotonin transporter
Therapy Area/IndicationsNeurocognitive DisordersDepressionLow Back Pain +[7] 
Global Approved IndicationsDepressionFibromyalgia
Approved Indications in ChinaDepression
Original Approved Country/TerritoryFrance
Original Approved Date1996/12/06
Country/TerritoryCzechiaUnited StatesSweden +[18] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPierre Fabre Group
China Registration ClassN/A

Develop Information

Active CompaniesPierre Fabre GroupAbbvie IncAsahi Kasei Corp +[4] 
Inactive CompaniesThe Brigham and Women's HospitalDuke UniversityColumbia University +[10] 
Active IndicationsDepressionFibromyalgia
Inactive IndicationsNeurocognitive DisordersLow Back PainBack Pain +[5] 

Other Information

ATC CodeN06AX17
Related LinksWikipediaDrugBankKEGG